– UK, London – Impax Asset Management Group plc (LON: IPX), the AIM-listed specialist investor focused on the transition to a more sustainable economy, today announced the appointment of Sally Bridgeland as Board Chair effective from 8 December 2020, succeeding Keith Falconer who retired as Chairman.
“I am very pleased that Sally is taking over as Impax’s Chair. Since she joined the Board in 2015, Sally has made a tremendous contribution to the Company’s strategic development both as an Independent Non-Executive Director and as Chair of the Audit & Risk Committee.” said CEO, Ian Simm.
The company also announced the appointment of Simon O’Regan to the Board as Non-Executive Director, effective 8 December 2020. Simon will sit on the Audit & Risk and Remuneration Committees.
Ian Simm continued: “On behalf of the Board, I’m delighted to welcome Simon O’Regan, who is a highly-experienced investment industry Non-Executive Director and business leader. Simon’s in-depth knowledge of international markets, including the United States, will be invaluable as we continue to develop our business globally.”
He added: “I would like to thank Keith for his inspiring leadership, his advice and dedication to Impax during his time as Chairman. His business acumen and judgement have greatly contributed to our success, and he will be sorely missed!”
Keith Falconer said: “I have had the honour of serving as Chairman since 2004. Over this time Impax has grown its assets under management from £59 million to more than £23 billion. We have accomplished much through bull and bear markets and there have been many notable milestones. Over these years we’ve benefited from notably low staff turnover, our investment philosophy has become widely accepted and ever more compelling, and we have maintained and developed our strong corporate culture. I am now retiring and am delighted that Sally Bridgeland will be appointed as Chair. I wish her all the best as she assumes the chair.”
About Sally Bridgeland
Sally became a Non-Executive Director of Impax in 2015 and has worked in the UK pensions industry for 30 years. She is also currently a Non-Executive Director of Royal London and the Local Pensions Partnership Ltd. Originally qualifying as a Fellow of the Institute of Actuaries with consultants Bacon & Woodrow, Sally was CEO of the BP Pension Fund from 2007-2014.
Sally Bridgeland said: “I am delighted to assume the role of Chair at such an exciting point in Impax’s history. I am very much looking forward to building on Keith’s work alongside my fellow Board members to deliver long-term success for the Company and create value for all our stakeholders.
“The commitment of policymakers, business leaders and wider society to forging a path towards a more sustainable economy has never been stronger. Against this backdrop, Impax’s well-established investment philosophy, broad range of investment solutions and acknowledged leadership position will stand the Company in good stead to deliver further value to clients over the coming years.”
About Simon O’Regan
Simon was previously CEO of Mercer’s US business before his retirement in 2017. He was also a member of the UK’s Nuclear Liabilities Financing Assurance Board until it submitted its final advice on Hinkley Point in 2015 and he is currently a Non-Executive Member of the Foreign, Commonwealth and Development Office’s Audit & Risk Assurance Committee.
Simon O’Regan said: “This is an exciting time to be joining the Impax Board. As the Company’s recent results show, Impax is enjoying a very strong period of growth with significant potential to expand further in international markets. I look forward to working with Ian, Sally and the rest of the Board to support the next chapter in its story.”
For more information: https://impaxam.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
